Risk of Death is Higher after Stent Postdilation in Patients with Acute Coronary Syndrome

Zhijiang Zhang,Yang Bi,Hao Xia,Hong Wang,Xiaopan Li,Zai-Peng Zhang,Yuan Ji
DOI: https://doi.org/10.1016/j.amjcard.2017.05.007
2017-01-01
Abstract:Karjalainen et al 1 Karjalainen P.P. Niemelä M. Laine M. Airaksinen J.K. Ylitalo A. Nammas W. Usefulness of post-coronary dilation to prevent recurrent myocardial infarction in patients treated with percutaneous coronary intervention for acute coronary syndrome (from the BASE ACS trial). Am J Cardiol. 2017; 119: 345-350 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar performed a post hoc analysis of the BASE ACS trial, a prospective randomized trial of titanium-nitride-oxide-coated bioactive stents versus everolimus-eluting stents in acute coronary syndrome (ACS). The primary end point was the first occurrence of major adverse cardiac events: a composite of cardiac death, nonfatal myocardial infarction (MI), or ischemia-driven target lesion revascularization. The secondary end points were noncardiac death and definite stent thrombosis. Their analysis showed that the rates of nonfatal MI were significantly lower among those who underwent postdilation versus those who did not (4.5% vs 8.5%, p = 0.02), while no significant differences were observed for other end points, including cardiac death, ischemia-driven target lesion revascularization, noncardiac death, or definite stent thrombosis. And the rates of the composite end point, major adverse cardiac events, were similar at long-term follow-up among patients who underwent stent postdilation versus those who did not (15.7% vs 15.1%, p = 0.81). Based on these findings, the investigators conclude that stent postdilation is useful in treating ACS. However, in our opinion, this is an uncritical acceptance of stent postdilation at face value without considering the increased risk of death.
What problem does this paper attempt to address?